1 ver time, but no change in the occurrence of aphthous ulcers.

2  thalidomide may promote the healing of oral aphthous ulcers.

3 p (55 percent) had complete healing of their aphthous ulcers after four weeks, as compared with only

4 peutic presently used in the clinic to treat aphthous ulcers and asthma, is an inhibitor of these kin

5                    Saliva from patients with aphthous ulcers and Behcet disease prone to oral ulcers

6 o of the more common oral mucosal disorders: aphthous ulcers and recurrent herpes simplex labialis.

7 virus (HIV)-associated conditions, including aphthous ulcers and wasting syndrome.

8  receive thalidomide had complete healing of aphthous ulcers at the 4-week endoscopic evaluation, com

9 led study of thalidomide as therapy for oral aphthous ulcers in HIV-infected patients.

10 s is ineffective at preventing recurrence of aphthous ulcers in HIV-infected persons.

11 reventing recurrences of oral and esophageal aphthous ulcers in patients with human immunodeficiency

12               The hypothesis tested was that aphthous ulcers may lack key extracellular matrix compon

13 not in pseudohairy leukoplakia lesions, oral aphthous ulcers, or oral KS lesions.